Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2017 08:00 ET | Source: Dimension Therapeutics

Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”

REGENXBIO Waives Matching Rights CAMBRIDGE, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (“Dimension”) (NASDAQ:DMTX) announced today that the Dimension Board of Directors...
September 19, 2017 08:00 ET | Source: Dimension Therapeutics

Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”

CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (Nasdaq:DMTX), a leader in discovering and developing new therapeutic products for people living with devastating...
September 18, 2017 15:10 ET | Source: Dimension Therapeutics

Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx

CAMBRIDGE, Mass., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (Nasdaq:DMTX) (“Dimension”), a leader in discovering and developing new therapeutic products for people living with...
August 31, 2017 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) Deficiency

Twelve trial sites recruiting patients with OTC deficiency in the United States, United Kingdom, Spain, and Canada Initial data from the company’s Phase 1/2 study anticipated by late 2017 CAMBRIDGE,...
August 08, 2017 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update

Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017 IND filings for GSDIa and Hemophilia A programs...
July 24, 2017 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics Announces Management Change

CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the...
June 27, 2017 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities

Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017 IND filings for GSDIa and Hemophilia A expected in...
May 10, 2017 08:00 ET | Source: Dimension Therapeutics

Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update

Discontinues Clinical Development of DTX101, an AAVrh10 Factor IX Gene Therapy Product Candidate for Moderate/Severe-to-Severe Hemophilia B Initial data from Phase 1/2 clinical trial of DTX301,...
April 24, 2017 12:05 ET | Source: Dimension Therapeutics

Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting

CAMBRIDGE, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting...
March 09, 2017 07:30 ET | Source: Dimension Therapeutics

Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing

In December, initiated Phase 1/2 clinical trial of DTX301, Dimension’s lead IMD product candidate for OTC Deficiency; Initial data expected 2H 2017 Updates interim results from Phase 1/2 clinical...